Po-Hung Chen, MD

Todd T. Brown, MD, PhD is a clinical investigator who focuses on body composition, metabolic, and skeletal abnormalities observed in people with HIV, particularly as related to aging. Through translational investigation, epidemiologic studies, and clinical trials, he has been interested in understanding the pathogenesis of glucose disorders, fat changes, hormonal dysregulation, and osteoporosis in people with HIV, the consequences of these conditions (eg cardiovascular disease, frailty), and their optimal evaluation and management.

Dr. Han Na Kim is a Clinical Associate and part-time Assistant Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism. Her clinical practice focuses on metabolic bone disease, including osteoporosis and hyperparathyroidism, as well as diabetes mellitus. She earned her medical degree from the University of Chicago Pritzer School of Medicine, completed her residency in Internal Medicine at New York University, and worked as a hospitalist at University of Pittsburgh Medical Center Presbyterian/Montefiore before pursuing an endocrinology fellowship at Johns Hopkins University School of Medicine. She sees patients at the Johns Hopkins Bayview Metabolic Bone and Osteoporosis Center and Green Spring Station Johns Hopkins Endocrinology Clinic (diabetes and thyroid patients only).

Johns Hopkins gastroenterologist David Muñiz Pedrogo is a physician-scientist who specializes in the treatment of inflammatory bowel disease (IBD). He sees patients who have ulcerative colitis and Crohn’s disease. A graduate of the University of Puerto Rico School of Medicine, Dr. Muñiz Pedrogo completed an internship and residency training in internal medicine at The Johns Hopkins Hospital, where he remained for fellowship training in gastroenterology and hepatology. He obtained advanced fellowship training in inflammatory bowel disease at the Mount Sinai Hospital in New York. Dr. Muñiz Pedrogo is the assistant director of the IBD clinical trials unit at Johns Hopkins. His research focuses on improving precision medicine for treatment of IBD by understanding the role of the immune system and gut microbiome in predicting response to various therapies and in predicting other clinical outcomes.